NCT00769587已完成2 期
Phase II Study of Thalidomide in Mastocytosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Objective reduction of the infiltration rate at 6 months
研究概览
简要总结
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease.
PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive systemic mastocytosis.
详细描述
OBJECTIVES:
Primary
- Determine the objective response rate at 6 months in patients with systemic mastocytosis treated with thalidomide.
Secondary
- Determine the tolerability of this drug in these patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Thalidomide
Experimental
Use of thalidomide
干预措施: thalidomide (Drug)
结局指标
主要结局
Objective reduction of the infiltration rate at 6 months
时间窗: 6 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian CancerOvarian CancerNCT00016224Memorial Sloan Kettering Cancer Center
已完成
2 期
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryMelanoma (Skin)NCT00104988SWOG Cancer Research Network64
已完成
2 期
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation TherapyBrain and Central Nervous System TumorsNCT00039468Dartmouth-Hitchcock Medical Center26
已完成
2 期
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or NeuroblastomaCentral Nervous System Tumor, PediatricNeuroblastomaNCT00098865Dana-Farber Cancer Institute15
已完成
2 期
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix CancerCarcinoma of the AppendixColorectal CancerNCT00310076Wake Forest University Health Sciences29